^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tavocept (dimesna)

    i
    Other names: LP-300, BNP7787
    Associations

    News

    Trials
    Company:
    BioNumerik, Lantern Pharma
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    Associations

    News

    Trials
    30d
    HARMONIC: A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (clinicaltrials.gov)
    P2, N=90, Recruiting, Lantern Pharma Inc. | Trial completion date: May 2025 --> Jun 2026 | Trial primary completion date: Nov 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    carboplatin • pemetrexed • Tavocept (dimesna)
    over1year
    Phase II Trial of LP-300 + Pemetrexed/Carboplatin in Patients Who Never Smoked with Lung Adenocarcinoma After TKI Progression (IASLC-WCLC 2023)
    The prior phase III trial evaluating LP-300 with paclitaxel/cisplatin demonstrated a marginal increase in survival in the overall study population. Patients who received TKIs as a prior therapy must have disease progression or treatment intolerance. Enrollment for this trial began in March of 2023.
    Clinical • P2 data
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase) • GLRX (Glutaredoxin)
    |
    MET exon 14 mutation
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • Tavocept (dimesna)
    2years
    HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (clinicaltrials.gov)
    P2, N=90, Recruiting, Lantern Pharma Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    carboplatin • pemetrexed • Tavocept (dimesna)
    over2years
    HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Lantern Pharma Inc.
    New P2 trial • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    carboplatin • pemetrexed • Tavocept (dimesna)